A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC
← catalyst calendarNCT05211895 · readout in 693 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →. With Arcus Biosciences, Inc..
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
860estimated
Sites
264
Countries
Belgium, Brazil, Canada +25
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-02-18 | actual | When the study began enrolling |
| Primary completion | 2028-07-12 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2030-10-01 | estimated | The whole study's end, after follow-up |
| First posted | 2022-01-27 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Non-Small Cell Lung Cancer
Interventions
- Drug: Durvalumab
- Drug: Domvanalimab
- Other: Placebo
Primary outcome
what the primary-completion date above is the date OFProgression Free Survival (PFS)
measured Up to 8 years after randomization
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed